Syndax Pharmaceuticals/SNDX

$19.72

-1.79%
-
1D1W1MYTD1YMAX

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing pipeline of cancer therapies. Its product candidates include revumenib, and axatilimab. It is developing revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant A. It is also exploring the use of revumenib as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.

Ticker

SNDX

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Michael Metzger

Employees

112

Headquarters

Waltham, United States
Website
syndax.com

SNDX Metrics

BasicAdvanced
$1.7B
Market cap
-
P/E ratio
-$3.22
EPS
1.02
Beta
-
Dividend rate
$1.7B
1.01694
$25.34
$11.22
1.1M
8.934
0.001
0.004
-47.99%
-51.89%
-51.84%
3.504
3.504
-33.1%

What the Analysts think about SNDX

Analyst Ratings

Majority rating from 13 analysts.
Buy

Price Targets

Average projection from 11 analysts.
73.33% upside
High $45.00
Low $23.00
$19.72
Current price
$34.18
Average price target

SNDX Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q1 24
QoQ growth
Revenue
$0
NaN%
Net income
-$72M
-0%
Profit margin
0%
NaN%

SNDX Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 13.14%
QuarterlyAnnual
Q2 23
Q3 23
Q4 23
Q1 24
Q2 24
Actual
-$0.64
-$0.73
-$1.00
-$0.85
-
Expected
-$0.73
-$0.80
-$0.99
-$0.98
-$0.92
Surprise
-12.59%
-8.23%
0.58%
-13.14%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Syndax Pharmaceuticals stock?

Syndax Pharmaceuticals (SNDX) has a market cap of $1.7B as of May 29, 2024.

What is the P/E ratio for Syndax Pharmaceuticals stock?

The price to earnings (P/E) ratio for Syndax Pharmaceuticals (SNDX) stock is 0 as of May 29, 2024.

Does Syndax Pharmaceuticals stock pay dividends?

No, Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders as of May 29, 2024.

When is the next Syndax Pharmaceuticals dividend payment date?

Syndax Pharmaceuticals (SNDX) stock does not pay dividends to its shareholders.

What is the beta indicator for Syndax Pharmaceuticals?

Syndax Pharmaceuticals (SNDX) has a beta rating of 1.02. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

What is the Syndax Pharmaceuticals stock price target?

The target price for Syndax Pharmaceuticals (SNDX) stock is $34.18, which is 73.33% above the current price of $19.72. This is an average based on projections from 11 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Syndax Pharmaceuticals stock

Buy or sell Syndax Pharmaceuticals stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing